ResMed Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$1.42B
↑+11.0% +$141Mvs FY2024 (Q4)
Gross Profit
$879M
↑+17.0% +$127Mvs FY2024 (Q4)
Operating Income
$492M
↑+17.8% +$74Mvs FY2024 (Q4)
Net Income
$393M
↑+13.9% +$48Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $1.42B | $1.28B |
| COGS | $544M | $531M |
| Gross Profit | $879M | $751M |
| R&D | $91M | $81M |
| SG&A | $278M | $242M |
| D&A | $18M | $11M |
| Other OpEx | $0 | $0 |
| Operating Income | $492M | $417M |
| Interest Exp. | $8M | $775K |
| Other Non-Op | $0 | $0 |
| Pretax Income | $484M | $416M |
| Tax | $91M | $72M |
| Net Income | $393M | $345M |
QuarterCharts · SEC EDGAR data · RMD · Comparing FY2025 (Q4) vs FY2024 (Q4)